Supplemental Material for Manuscript “Genome-wide DNA methylation analysis
pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome
with isolated deletion (5q): results from a prospective multicenter study of the
German MDS study group”, Annals of Hematology

Anna Hecht¹, Julia A. Meyer², Johann-Christoph Jann¹, Katja Sockel³, Aristoteles Giagounidis⁴,
Katharina S. Götze⁵, Anne Letsch⁶, Detlef Haase⁷, Richard F. Schlenk⁸, Torsten Haferlach⁹,
Philippe Schaffhausen¹⁰, Gesine Bug¹¹, Michael Lübbert¹², Felicitas Thol¹³, Guntram Büsche¹⁴,
Esther Schuler¹⁵, Verena Nowak¹, Julia Obländer¹, Stephanie Fey¹, Nadine Müller¹, Georgia
Metzgeroth¹, Wolf-Karsten Hofmann¹, Ulrich Germing¹⁵, Florian Nolte¹, Mark Reinwald¹⁶ and
Daniel Nowak¹.

¹Department of Hematology and Oncology, University Hospital Mannheim, Mannheim,
Germany; ²Department of Pediatrics, University of California San Francisco, San Francisco,
USA; ³Department of Hematology, University Hospital Dresden, Dresden, Germany;
⁴Department of Hematology, Oncology and Palliative Care, Marien Hospital Duesseldorf,
Duesseldorf, Germany; ⁵Department of Internal Medicine, Technical University of Munich,
Munich, Germany; ⁶Department of Hematology and Oncology, Charité, Benjamin Franklin
University, Berlin, Germany; ⁷University Medicine Goettingen, Clinics of Hematology and
Medical Oncology, Goettingen, Germany; ⁸Department of Internal Medicine V, Heidelberg
University Hospital, Germany; ⁹MLL Munich Leukemia Laboratory, Munich, Germany;
¹⁰Department of Oncology, Hematology, BMT with section Pneumology, Hubertus Wald Cancer
Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¹¹Department of
Internal Medicine, University Hospital Frankfurt, Frankfurt, Germany; ¹²University Hospital
Freiburg, Internal Medicine, Freiburg, Germany; ¹³Department of Hematology, Hemostasis,
Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;
¹⁴Hannover Medical School, Institute of Pathology, Hannover, Germany; ¹⁵Department for
Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University,
Duesseldorf, Germany; ¹⁶Brandenburg Medical School Theodor Fontane, Brandenburg an der
Havel, Germany.

Corresponding author: Anna Hecht, MD, E-Mail: anna.hecht@medma.uni-heidelberg.de
Supplemental Figure 1: Overall survival of the 51 patients depending on gender estimated using the Kaplan-Meier method.
Supplemental Figure 2: Unsupervised clustering of 44 patient bone marrow samples prior to lenalidomide treatment. Patients with mutations in TP53 were excluded from analysis. After exclusion of TP53mut patients, each of the TP53wt patients still clusters in the same way as before when analyzing the whole cohort. Patients are displayed on the X axis and the 1534 most variable CpG sites are displayed on the Y axis. Information on transfusion independence, cytogenetic remission and death is shown at the top of the figure.
Supplemental Figure 3. Overall survival of the 44 patients without TP53 mutations was estimated using the Kaplan-Meier method. Patients are differentiated by Cluster A and B (compare to Supplemental Figure 2).